The company is expanding sites in Greenville, NC, Swindon, U.K., and Ferentino and Monza, Italy. The investments will add 15 development and current good manufacturing practice commercial production lines. The additions will support a range of capabilities in live virus, aseptic liquid handling, and lyophilized vial filling. Cumulatively, the projects will create approximately 1,000 new jobs and be completed over the next two years.

In other news, the company is also adding a new sterile manufacturing facility in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.

Thermo Fisher unveils new isotopic mass spectrometry system
Thermo Fisher has announced it has designed a new high-resolution mass spectrometry system for accurately extracting isotopic data from very small samples.

Thermo Fisher partners with Northeastern University
Thermo Fisher Scientific and Northeastern University have partnered to advance analytical capabilities and boost the biopharmaceutical industry.

Thermo Fisher expands collaboration with Symphogen
Thermo Fisher Scientific has expanded its collaboration with Symphogen to support that company's efforts to provide therapeutic proteins for biopharmaceutical...

Thermo Fisher expands Direct-to-Patient clinical trial service
Thermo Fisher Scientific said it has expanded its Direct-to-Patient clinical trial service to enable clinical trial medications to be delivered directly...

Thermo Fisher's Q3 earnings boosted by COVID-19 sales
Products related to the novel coronavirus are spelling success for Thermo Fisher, which reported that revenue was up by 36% in the third quarter to $8.52 billion,...